Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate-mefloquine versus artemether-lumefantrine for uncomplicated falciparum malaria in African children
ISRCTN17472707Phase 4Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Oct 2010
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of artesunate, mefloquine, artemether and lumefantrine in Malaria (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: PCR-corrected adequate clinical and parasitological response on Day 63. Started Oct 2010; status: completed.
02
Drugs
artesunatemefloquineartemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on ISRCTN17472707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17472707.